CardioNet, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on diagnosing and monitoring cardiac arrhythmias, announced today the release of a new application for the iPad, designed to provide physicians and their support staff easy access to the cardiac monitoring services at CardioNet.

Joseph Capper, CEO and President for CardioNet commented, “We are pleased to offer the thousands of physicians who prescribe MCOT, the most advanced cardiac monitoring system on the market, easier accessibility to patient data. Starting today, we launched an iPad application which allows health care providers to instantly access cardiac monitoring reports on-line. We believe that making the most precise mobile cardiac-related information available to physicians at their fingertips, in a user-friendly format, is a powerful tool that will benefit patients, payors and physicians alike.”

The new CardioNet Access App, currently available for free download at the Apple store, will enable physicians to save, print and send patient reports from the convenience of their iPad.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry^TM (MCOT^TM). More information can be found at http://www.cardionet.com.

Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company’s future. These statements may be identified by words such as “expect,” “may,” “anticipate,” “possible,” “estimate,” “potential,” “intend,” “plan,” “believe,” “forecast,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effectiveness of our efforts to address operational initiatives, including cost savings initiatives that affect our business, changes to insurance coverage, relationships with our government and commercial payors and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services and patent protection, adverse regulatory action and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.